Speakers 2023

Speakers 2022 2023

Christophe FERRAND

RIGHT INSTITUTE


CAR-T CELLS (KURSAAL CONF ROOM)

September 20th

Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft versus Leukemia, GvL), respectively. Based on the suicide gene therapy clinical trial (TKO), using ex-vivo Gene Modified T-cells (GMTC) and initiated in 2001 by our team, I have naturally redirected my research activity towards CART- cells immunotherapies by developing new approaches targeting original Tumor Associated Antigens expressed in Leukemia. My involvement in this gene therapy trial did allow me to a great experience in GMTC, their production and monitoring. In parallel, I have strongly contributed, as the scientific responsible, to bring the new suicide gene (iCASP9/AP1903) clinical trial Side by CIDe to the French regulatory agency (ANSM) approval (in the context of the new ATMP European regulations). This trial (ClinicalTrials.gov Identifier: NCT02849886), will use gene modified T cells produced ex-vivo and is now open for patient recruitment With competences in immunology, vectorology (lenti or retrovirus), cell culture, gene therapy, suicide gene therapy, but also as Head of the Molecular Onco-Hematology Lab, I have an interesting background in the field of Immunotherapies (CART-cells, TgTCR) that may be applied to hematology.

Find also


Marina DESCHAMPS

RIGHT INSTITUTE

From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...

En savoir +

Melanie RIETENBACH

Miltenyi Biotec

Melanie Rietenbach is a Global Product Manager for the Immunotherapy portfolio at Miltenyi Biotec. During the last 3 years, she has been working together with the R&D and Clinical Development Team in order to advance the development of tools to...

En savoir +

Sylvain PERRUCHE

RIGHT INSTITUTE

A doctor in biology, the Bisontinental Inserm researcher worked for nearly ten years within Inserm's Joint Research Unit 1098 - hosted by the Etablissement français du sang Bourgogne-Franche-Comté, in Besançon - in the development of therapeutic approaches to control the...

En savoir +

Oriane BLANQUIE

EMA

After completing my pharmacy studies in Paris, France, I did a PhD in Neuroscience at the University Medical Center of Mainz, Germany (2013-2017), followed by a postdoc at the German Center for Neurodegenerative Diseases in Bonn, Germany (2017 – 2018)....

En savoir +

Peihua (Peggy) LU

Lu Daopei Hospital and Lu Daopei Institute of Hematology

Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University  Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.  American Board Certified Hematologist & Oncologist, with American and Chinese Medical License. Member of the Fourth Executive Committee of the...

En savoir +